Risk factors: Oncotype DX® assay predicts local recurrence in breast cancer

Nature Reviews Clinical Oncology

Volumn 7, Issue 6, 2010, Pages 300-

  Kirk, Rebecca ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TAMOXIFEN;

21 GENE RECURRENCE SCORE ASSAY; ARTICLE; ASSAY; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL (TOPIC); HUMAN; MASTECTOMY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; BREAST TUMOR; CHRONIC DISEASE; DIAGNOSTIC PROCEDURE; FEMALE; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; RISK FACTOR;

BREAST NEOPLASMS; CHRONIC DISEASE; FEMALE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; RISK FACTORS; CLINICAL LABORATORY TECHNIQUES;

EID: 77953158672     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2010.75     Document Type: Article

References (1)

1. Mamounas, E. P. et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J. Clin. Oncol. 28, 1677-1683 (2010)